3-DAY INTRAVESICAL INSTILLATION OF ANTICANCER DRUGS FOR PROPHYLAXIS OF BLADDER-CANCER

In this study, evaluation was made of the longterm outcome of 3-day in travesical instillation as adjuvant treatment immediately after transu rethral resection of superficial transitional cell carcinoma of the bl adder. Antitumor solution was instilled intravesically for 3 consecuti ve days following TUR of the primary lesion in 71 patients. All patien ts were randomly divided into three treatment groups. Mean intervals t o the first recurrence for BLM (50.2 months) was statistically signifi cant compared with the MMC (18.1 months) group (p=0.0485). Disease-fre e survival as determined by the Kaplan-Meier method in MMC, DOX and BL M was 55.0%, 60.4% and 76.2% at 2 years and 45.3%, 41.2% and 40.7% at 10 years, respectively. Postoperative 3-day intravesical instillation was found safe and may be useful for prophylaxis of bladder cancer rec urrence.